Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Plasma therapy

This page shows the latest Plasma therapy news and features for those working in and with pharma, biotech and healthcare.

Takeda therapy shows promise in rare blood clotting disorder

Takeda therapy shows promise in rare blood clotting disorder

Phase 3 results show the enzyme replacement therapy reduced thrombocytopenia events by 60%. ... The current standard of care (SoC) for cTTP is plasma therapy, which Takeda describes as ‘insufficient in restoring ADAMTS13, time-consuming, and costly’.

Latest news

  • Takeda begins development of COVID-19 plasma therapy Takeda begins development of COVID-19 plasma therapy

    Takeda aims to develop an anti-SARS-CoV-2 polyclonal hyperimmune globin, a plasma-derived drug, which will harness the blood of coronavirus patients who have recovered from their infections. ... According to Takeda, plasma-derived therapies have

  • China backs use of Roche’s Actemra for coronavirus China backs use of Roche’s Actemra for coronavirus

    Takeda has started developing a plasma-derived therapy – a polyclonal hyperimmune globulin called TAK-888 – that is intended to treat high-risk individuals with the virus. ... The passive immunotherapy is produced from pathogen-specific antibodies

  • Sanofi gets US okay for $270,000 blood disorder drug Cablivi Sanofi gets US okay for $270,000 blood disorder drug Cablivi

    First in a new class of single-domain antibody fragments drugs. Sanofi has FDA approval for its acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi, the principle asset behind its 3.9bn ... The US approval – which comes a few months

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    deficiency. The product works as replacement therapy and temporarily increases plasma levels of factor X, helping to prevent and control bleeding, according to the EMA. ... new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide)

  • BPL bags FDA approval for rare bleeding disorder therapy BPL bags FDA approval for rare bleeding disorder therapy

    The new therapy is a plasma-derived Factor X that has been approved by the FDA for on-demand control, of bleeding episodes in patients aged over 12, as well as ... The US regulator notes that treatment is usually based on giving fresh plasma or

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Quick links